Skip to main content
. Author manuscript; available in PMC: 2021 Oct 10.
Published in final edited form as: J Control Release. 2020 Jul 16;326:222–244. doi: 10.1016/j.jconrel.2020.07.011

Figure 8.

Figure 8.

Dual-ligand modified liposomes for local targeted delivery of anticancer drug for treatment of lung cancer. (A) Illustration of the preparation of dual-ligand triptolide (TPL)-loaded liposomes. (B) Representative bioluminescent images and corresponding lung tissue of the mice at day 31 after tumor inoculation. Mice were treated with free triptolide (TPL) and TPL delivered by liposomes (TPL-Lip), anti-carbonic anhydrase IX antibody-modified liposomes (CA IX-TPL-LIP), CPP33-modified liposomes (CPP33-TPL-Lip) or dual-ligand TPL liposomes (DL-TPL-Lip). Mice bearing orthotopic lung tumor were treated every three days four times by intratracheal administration at 0.3 mg/kg of tested substances. Redrawn from [189].